Congress trades and big insider sales, sent the day they're filed. Free.
Open in TelegramCHIEF FINANCIAL OFFICERCIK 0001882764
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 0 | Hohl BenjaminCHIEF FINANCIAL OFFICER |  ELVNEnliven Therapeutics, Inc.Option exercise · 10b5-1 plan | M | $89K 6,018 sh | Oct 21, 2026 traded Oct 19, 2026 | |
Hohl BenjaminCHIEF FINANCIAL OFFICER |
| ELVNEnliven Therapeutics, Inc. Option exercise · 10b5-1 plan |
| M |
| — 6,018 sh |
| Oct 21, 2026 traded Oct 19, 2026 |
| 10 | Hohl BenjaminCHIEF FINANCIAL OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $232K 6,018 sh | Oct 21, 2026 traded Oct 19, 2026 |
| 13 | Hohl BenjaminCHIEF FINANCIAL OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $111K 2,194 sh | Sep 21, 2026 traded Sep 17, 2026 |
| 0 | Hohl BenjaminCHIEF FINANCIAL OFFICER | ELVNEnliven Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 3,982 sh | Sep 21, 2026 traded Sep 17, 2026 |
| 13 | Hohl BenjaminCHIEF FINANCIAL OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $177K 3,535 sh | Sep 21, 2026 traded Sep 17, 2026 |
| 6 | Hohl BenjaminCHIEF FINANCIAL OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $15K 289 sh | Sep 21, 2026 traded Sep 17, 2026 |
| 2 | Hohl BenjaminCHIEF FINANCIAL OFFICER | ELVNEnliven Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $59K 3,982 sh | Sep 21, 2026 traded Sep 17, 2026 |
| 11 | Hohl BenjaminCHIEF FINANCIAL OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $270K 4,630 sh | Aug 19, 2026 traded Aug 17, 2026 |
| 4 | Hohl BenjaminCHIEF FINANCIAL OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $82K 1,388 sh | Aug 19, 2026 traded Aug 17, 2026 |
| 18 | Hohl BenjaminCHIEF FINANCIAL OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $149K 3,401 sh | Jun 22, 2026 traded Jun 17, 2026 |
| 14 | Hohl BenjaminCHIEF FINANCIAL OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $55K 1,238 sh | Jun 22, 2026 traded Jun 17, 2026 |
| 9 | Hohl BenjaminCHIEF FINANCIAL OFFICER | ELVNEnliven Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 6,018 sh | Jun 22, 2026 traded Jun 17, 2026 |
| 14 | Hohl BenjaminCHIEF FINANCIAL OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $59K 1,379 sh | Jun 22, 2026 traded Jun 17, 2026 |
| 9 | Hohl BenjaminCHIEF FINANCIAL OFFICER | ELVNEnliven Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $15K 6,018 sh | Jun 22, 2026 traded Jun 17, 2026 |
| 13 | Hohl BenjaminCHIEF FINANCIAL OFFICER | ELVNEnliven Therapeutics, Inc. Option exercise | M | — 13.0K sh | Dec 23, 2025 traded Dec 22, 2025 |
| 21 | Hohl BenjaminCHIEF FINANCIAL OFFICER | ELVNEnliven Therapeutics, Inc. Option exercise | M | $32K 13.0K sh | Dec 23, 2025 traded Dec 22, 2025 |